PepTivator
®
EBV BZLF1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acid (aa) overlap, covering the complete sequence of the Epstein-Barr virus BZLF1 protein (UniProt ID: P03206).
PepTivator peptide pools have been developed for the efficient
in vitro
stimulation of antigen–specific CD4
+
and CD8
+
T cells as peptides of 15-aa length with 11-aa overlap represent an optimized solution for stimulating both CD4
+
and CD8
+
T cells in various applications.
1
Quantitative, phenotypical, or functional analysis of EBV BZLF1–specific T cell immunity can provide important information on the

Data and images for
PepTivator
®
EBV BZLF1
, human

Figures

Figure 1

View details
Production of IFN-γ by human CD4
+
or CD8
+
T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Figure 1

Production of IFN-γ by human CD4
+
or CD8
+
T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Specifications for
PepTivator
®
EBV BZLF1
, human

Overview

PepTivator
®
EBV BZLF1 is a peptide pool that consists mainly of 15-mer peptides with 11 amino acid (aa) overlap, covering the complete sequence of the Epstein-Barr virus BZLF1 protein (UniProt ID: P03206).
PepTivator peptide pools have been developed for the efficient
in vitro
stimulation of antigen–specific CD4
+
and CD8
+
T cells as peptides of 15-aa length with 11-aa overlap represent an optimized solution for stimulating both CD4
+
and CD8
+
T cells in various applications.
1
Quantitative, phenotypical, or functional analysis of EBV BZLF1–specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.
PepTivator EBV BZLF1-HT is a peptide pool lyophilized in the wells of a 96-well plate, allowing stimulation and analysis of cells directly on the plate.
The convenient 96-well format, composed of 12 individually removable strips of 8 wells each allows for easy and flexible experimental set-up, different antigens can be combined by assembling different strips. A control can also be added easily by using strips from the Control plate (12x8).

Detailed product information

Background information

Epstein-Barr virus (EBV) is a human γ-herpesvirus with B cell growth–transforming ability and lymphomagenic potential. More than 90% of human adults are infected with EBV. Usually the primary infection is asymptomatic, but some individuals develop an infectious mononucleosis, a self-limiting lymphoproliferative disease. BZLF1 activates a promoter of an EBV gene and plays a key role in the switch from latent to productive infection of EBV. BZLF1-specific CD4
+
and CD8
+
T cells have been found in EBV-infected individuals.
2–4

Downstream applications

The
in vitro
stimulation of EBV BZLF1–specific CD4
+
and CD8
+
T cells with PepTivator EBV BZLF1 causes the secretion of effector cytokines and the upregulation of activation markers, which then allow the detection and isolation of EBV BZLF1–specific T cells
5
:
  • Detection and analysis of EBV BZLF1–specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular cytokine staining, or other technologies.
  • Isolation of viable EBV BZLF1–specific CD4+ T cells with the CD154 MicroBead Kit, or of CD4+ and CD8+ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay – Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of EBV BZLF1–specific CD4+ and CD8+ effector/memory T cells from naive T cell populations for research on immunotherapy and vaccination.
  • Pulsing of antigen-presenting cells, for example, for research on dendritic cell vaccination.

References for
PepTivator
®
EBV BZLF1
, human

Publications

  1. Kiecker, F. et al. (2004) Analysis of antigen-specific T-cell responses with synthetic peptides--what kind of peptide for which purpose? Hum. Immunol. 65: 523-536
  2. Saulquin et al. (2000) A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur. J. Immunol. 30: 2531-2539
  3. Precopio, M. L. et al. (2003) Differential kinetics and specificity of EBV-specific CD4+ and CD8+ T cells during primary infection. J. Immunol. 170: 2590-2598
  4. Tynan, F. E. et al. (2005) The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J. Exp. Med. 202: 1249-1260
  5. Dodero A. et al. (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113: 4771-4779

Related products for
PepTivator
®
EBV BZLF1
, human

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?